Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors.

Archives of General Psychiatry (Impact Factor: 13.75). 04/1994; 51(3):248-51.
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: Stillen™ has been used to treat patients with gastric mucosal ulcers and has an anti-inflammatory effect. It is well-known that neuro-inflammatory reactions are related to depression. Here we evaluated the antidepressant-like effect of Stillen™ on mice subjected to the forced swimming test (FST). Stillen™ and eupatilin (a major component of Stillen™) significantly decreased immobility times compared with the FST control group. In the Stillen™-administered group, increased levels of 5-hydroxytryptamine (serotonin) and brain-derived neurotrophic factor protein were observed in the hippocampus. Nissl bodies also increased in the hippocampus neuronal cytoplasm of the Stillen™-administered group. Stillen™ decreased levels of interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (at the mRNA and protein levels) in the hippocampus and serum, compared with the control group. In addition, the mRNA expression of estrogen receptor-β increased after Stillen™ administration in the hippocampus. These findings suggest that Stillen™ should be viewed as a candidate antidepressant.
    Archives of Pharmacal Research 08/2014; DOI:10.1007/s12272-014-0472-8 · 1.54 Impact Factor
  • Source
    European Neuropsychopharmacology 10/2003; Suppl 4(13):204-205. DOI:10.1016/S0924-977X(03)91781-0 · 5.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: VORTIOXETINE IS A NEW MULTIMODAL ACTION ANTIDEPRESSANT WITH TWO TYPES OF ACTION: serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic receptors. It is an antagonist of the 5-HT3 and 5-HT7 receptors, a partial agonist of 5-HT1B, and an agonist of 5-HT1A. Its combined action on SERT and four subtypes of serotoninergic receptors increases the extracellular concentration of serotonin, dopamine, and noradrenaline. Twelve clinical trials have been carried out, nine of which had positive results versus placebo. When active comparators were included in the study design, no significant differences were found except in one study in which the efficacy of vortioxetine was superior to the comparator (agomelatine) in depression resistant to selective serotonin reuptake inhibitors (SSRI)/serotonin-norepinephrine reuptake inhibitors (SNRI) treatment. Tolerability studies indicate that the drug does not cause any important problems on blood tests, vital signs, or on electrocardiography. The lack of weight gain and induction of metabolic syndrome and the lack of significant changes in the QTc are especially important. The incidence rate of sexual dysfunction is low and similar to placebo in various trials. Similarly, cognitive function remains intact with vortioxetine.
    Neuropsychiatric Disease and Treatment 07/2014; 10:1297-307. DOI:10.2147/NDT.S41387 · 2.00 Impact Factor
    This article is viewable in ResearchGate's enriched format